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Accepted 5 April 2013Umbilical cord blood transplantation (UCBT) has
become a widely available and accepted alternative stem
cell source for pediatric and adult patients with malignant
and nonmalignant hematologic diseases [1-4]. Over the last
several years, multiple studies have reported lower rates of
graft-versus-host disease (GVHD), both grade III-IV acute
GVHD (aGVHD) and chronic GVHD (cGVHD), in UCBT
recipients compared with recipients of unrelated donor
peripheral blood or bone marrow hematopoietic cell
transplantation (HCT) [5-7]. However, the more recent
decreased use of antithymocyte globulin as part of the
conditioning regimen, the almost uniform use of combi-
nation cyclosporine and mycophenolate mofetil therapy for
GVHD prophylaxis, and the increased use of 2 cord blood
units (versus 1 unit) warrant a reevaluation of the inci-
dence of aGVHD and cGVHD after UCBT. Furthermore, the
rate of cGVHD reported after UCBT in the previous studies
was determined using the traditional clinical diagnostic
criteria (limited versus extensive), without taking in
consideration the 2005 National Institutes of Health (NIH)
consensus criteria [8].
Ponce et al. [9] conducted a single-center study in 115
pediatric and adult patients with hematologic malignancies
who underwent double UCBT (dUCBT) to assess the inci-
dence and manifestations of both aGVHD and cGVHD. The
authors reported an incidence of grade II-IV acute GVHD of
53% at day þ180, which was similar to the rate previously
reported by MacMillan et al. [5]. However, the data of Ponce
et al. identify the gastrointestinal (GI) tract, not the skin, as
the most commonly affected organ, with GI involvement in
80% of patients with grade II-IV aGVHD. This ﬁnding
conﬁrms previously reported results in a cohort of 79
pediatric UCBT recipients [10]. The propensity of isolated GI
aGVHD reinforces the importance of using endoscopic
biopsy for diagnosis when symptoms are limited to this
single organ system.Financial disclosure: See Acknowledgments on page 848.
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http://dx.doi.org/10.1016/j.bbmt.2013.04.006Interestingly, 85% of patients with grade II aGVHD
affecting the upper and/or lower GI tract responded to
budesonide treatment alone, without the need for systemic
corticosteroids. As Ponce et al. highlight, this favorable
response to budesonide merits further exploration in
prospective clinical trials with the goal of reducing exposure
to systemic corticosteroids.
Previous studies have found an increased incidence of
grade II-IV aGVHD after dUCBT compared with single UCBT
[5]; however, there is no clear evidence of an increased risk
of grade III-IV aGVHD after dUCBT. Although the analysis of
Ponce et al. was limited to dUCBT, they found a higher
incidence of grade III-IV aGVHD (23%) than reported previ-
ously [3,5]. Similarly, at our institution, we recently reported
a 30% incidence of grade III-IV aGVHD after single UCBT and
dUCBT [11]. Although the limitations of single-center studies
do not allow for any deﬁnitive conclusions, these ﬁndings
suggest that grade III-IV aGVHD after dUCBT is relatively
common, affecting up to one-quarter of HCT recipients.
Risk factors for aGVHD after UCBT vary among reports
[2,5,12]. Ponce et al. focused their analysis on the associationof
grade III-IV andHLAdisparity. Using high-resolution typing of
HLA-A, -B, and -DRB1, they found that 38% of transplanted
cord blood units were <4/6 HLA alleleematched to the
recipient. As might be expected, they found that a better HLA
match (>4/6 alleles) between the engrafting unit and the
recipient was associated with a lower incidence of severe
aGVHD. No increased risk of aGVHD was associated with the
degree of uniteunit matching.
Ponce et al. also investigated the potential role of total
nucleated cell and CD3þ infused cell dose, but found no
signiﬁcant associations. The advantages associated with
better HLA allele matching support the idea that high-
resolution typing for HLA-A, -B, and -DRB1 loci might
further improve unit selection algorithms, but could limit
donor selection. Although the data suggest that the incidence
of grade III-IV aGVHD after UCBT is higher than previously
thought and comparable to that seen after conventional
unrelated HCT [13-15], it must be kept in mind that the
majority of the UCBT recipients received 2 HLA anti-
genemismatched transplantations.
More than one-half (53%) of the UBCT recipients who
survived past day þ100 had active GVHD after day þ100. The
majority of these patients had persistent or recurrent aGVHD,
but2patientshad late-onset aGVHD.Almostone-quarter (23%)
of the patients with traditionally deﬁned cGVHD met the NIH
criteria for cGVHD. One-Half of these patients presented with
NIH overlap subtype, and the remainder met the NIH-deﬁned
subtype of classic cGVHD. Based on the new NIH criteria, the
incidence of any GVHDwas 54% at 2 years after UCBT. This rate
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Despite this high incidence, 34% of the patients had dis-
continued immunosuppressive therapy by 1 year after dUCBT.
At our institution, we recently investigated the preva-
lence of clinical manifestations of cGVHD after UCBT
according to the NIH criteria. We found a similarly high
incidence of any cGVHD at 2 years, with results comparable
to those observed after HLA-matched related and unrelated
donor HSCT. Furthermore, in our analysis, a similar per-
centage of patients successfully discontinued immunosup-
pression [11]. These concurrent and comparable ﬁndings
suggest that GVHD in the setting of UCBTmight resolvemore
quickly and express a more positive response to treatment.
In conclusion, the study of Ponce et al. speciﬁcally
addressed the incidence and risk factors of GVHD after
dUCBT using non-antithymocyte globulinebased regimens,
taking into account HLA allele-level matching and using the
NIH consensus criteria for cGVHD. Keeping in mind the in-
creased level of HLA disparity tolerated in UBCT, the fol-
lowing main points emerge: (1) The incidence of aGVHD can
be considered comparable to that seen after other types of
unrelated HCT; (2) the aGVHD involvement of the GI tract
appears to predominate, but responds well to single-agent
budenoside treatment in the case of grade II disease; (3)
cord blood unit selection using high-resolution typing might
help reduce the risk of grade III-IV aGVHD; and (4) reclas-
siﬁcation of GVHD after day þ100 based on the NIH criteria
showed that cGVHD after UCBT seems to be present mostly
as persistent and recurrent ﬂares of aGVHD. Taken together,
these results underscore the need for adequate GVHD
prophylaxis after dUCBT. In the light of these ﬁndings,
a larger multicenter study is needed with the aim of testing
reproducibility among different transplantation centers.
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